RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Amgen Inc.

A collection of news and information related to Amgen Inc. published by this site and its partners.

Top Amgen Inc. Articles see all

Displaying items 1-5
  • Merger of Aecom and URS to create giant L.A. construction firm

    Los Angeles construction giant Aecom Technology Corp. — which has worked on downtown L.A. high-rises, World Cup stadiums and New York's new World Trade Center — will buy its San Francisco rival, URS Corp., in a $6-billion deal.
  • A fraud accusation like nothing you've seen before

    A fraud accusation like nothing you've seen before
    It can be hard to keep up with the latest examples of fraud rings and other organized wrongdoing, but here's one that takes the cake: the scientific monthly Journal of Vibration and Control is retracting 60 articles "implicated in a peer review and...

    Exclusive: U.S. approval of Merck cancer immunotherapy expected soon

    Exclusive: U.S. approval of Merck cancer immunotherapy expected soon
    U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation. If approved by the...

    Amgen reports positive results from analysis of its blood cancer drug

    Amgen reports positive results from analysis of its blood cancer drug
    Biotech giant Amgen Inc. said a preliminary analysis of its prized blood cancer drug showed patients who took it fared better than those using the standard treatment. The Thousand Oaks company said that patients with relapsed multiple myeloma who took...

    Amgen to lay off up to 2,900 workers and close plants in two states

    Biotech giant Amgen Inc. said it would lay off up to 2,900 employees and close facilities in Washington state and Colorado, as the Thousand Oaks company moved to reign in expenses and focus on new drugs. Those cuts could amount to nearly 15% of its 20,...